tirzepatide shortage over I was wrong. I was assuming the best and now see it differently. You caught it. So I dug in, and the real story is worse than what I said. I called Lilly's weight-loss drug removed from

States worry about being too stringent for fear of taking away jobs, but the FDA cant possibly oversee thousands of compounding pharmacies alone, she said

Tirzepatide is administered as a once-weekly subcutaneous injection, with doses ranging from 2.5 mg to 15 mg depending on the indication and individual response

Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026

This, the report argues, is driven by easier access to unhealthy options compared with healthier choices